---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/41673761.md"
description: "$REMEGEN(09995.HK) and $HENGRUI PHARMA(01276.HK) both edged up slightly. In the innovative drug sector, there's a new overseas business development deal that catches the eye every few weeks, and licensing-out has evolved from an event into a business model. The debate now shifts to valuation methods—should it be based on pipeline NPV, or should a premium be given for "BD options"? It makes sense to give an option premium to platform-type companies like $HENGRUI PHARMA(01276.HK), but doing the same for single-product biotech companies is a bubble. Do you think the market can distinguish between these two?"
datetime: "2026-06-10T10:46:24.000Z"
locales:
  - [en](https://longbridge.com/en/topics/41673761.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/41673761.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/41673761.md)
author: "[Dimoo](https://longbridge.com/en/profiles/26968366.md)"
---

# $REMEGEN(09995.HK) and $HENGRUI PHARMA(01276.HK) b…


### Related Stocks

- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)
- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)